Skip to main content
Clinical Trials/NL-OMON42142
NL-OMON42142
Completed
Not Applicable

The regenerative surgical treatment of intra-bony peri-implantitis defects with Endobon® (test) versus an established bovine derived bone mineral (control) - Endobon versus BioOss

Vrije Universiteit0 sites40 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
infecties rondom tand implantaten
Sponsor
Vrije Universiteit
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • During surgical exploration an intra\-bony component of at least 3 mm at the deepest point must be present.
  • The defect should have a minimum of 3 osseous walls (a circumference of the osseous defect of at least 270 degrees). Only 3 and 4 wall intraosseous defects will be included.
  • The defect must not be wider than 4 mm and the defect angle must be less than 35 degrees from axis of implant.

Exclusion Criteria

  • Subjects with diabetes mellitus (HbAlc \>\= 6\.5%)
  • Subjects taking corticosteroids or other anti\-inflammatory prescription drug
  • Subjects taking medications known to induce gingival hyperplasia
  • Subjects must not be allergic to penicillin or metronidazole
  • Subjects with a history of taking systemic antibiotics in the preceding month
  • Subjects must not be pregnant or lactating
  • Implants placed in grafted bone or previously augmented with bone substitute or other type of regenerative material
  • If stability of the Endobon® granules or control granules cannot be accomplished in the defect
  • Failure of obtaining soft tissue closure
  • Mobile implants

Outcomes

Primary Outcomes

Not specified

Similar Trials